Salivary potassium measured by genetically encoded potassium ion indicators as a surrogate for plasma potassium levels in hemodialysis patients-a proof-of-concept study.


Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
28 02 2023
Historique:
received: 15 02 2022
pubmed: 15 6 2022
medline: 4 3 2023
entrez: 14 6 2022
Statut: ppublish

Résumé

Hyperkalemia is a common complication in cardiorenal patients treated with agents interfering with renal potassium (K+) excretion. It frequently leads to discontinuation of potentially life-saving medication, which has increased the importance of K+ monitoring. Non-invasive means to detect hyperkalemia are currently unavailable, but would be of potential use for therapy guidance. The aim of the present study was to assess the analytical performance of genetically encoded potassium-ion indicators (GEPIIs) in measuring salivary [K+] ([K+]Saliva) and to determine whether changes of [K+]Saliva depict those of [K+]Plasma. We conducted this proof-of-concept study: saliva samples from 20 healthy volunteers as well as plasma and saliva from 29 patients on hemodialysis (HD) before and after three consecutive HD treatments were collected. We compared [K+]Saliva as assessed by the gold standard ion-selective electrode (ISE) with GEPII measurements. The Bland-Altmann analysis showed a strong agreement (bias 0.71; 95% limits of agreement from -2.79 to 4.40) between GEPII and ISE. Before treatment, patients on HD showed significantly higher [K+]Saliva compared with healthy controls [median 37.7 (30.85; 48.46) vs 23.8 (21.63; 25.23) mmol/L; P < .05]. [K+]Plasma in HD patients decreased significantly after dialysis. This was paralleled by a significant decrease in [K+]Saliva, and both parameters increased until the subsequent HD session. Despite similar kinetics, we found weak or no correlation between [K+]Plasma and [K+]Saliva. GEPIIs have shown an excellent performance in determining [K+]Saliva. [K+]Plasma and [K+]Saliva exhibited similar kinetics. To determine whether saliva could be a suitable sample type to monitor [K+]Plasma, further testing in future studies are required.

Sections du résumé

BACKGROUND
Hyperkalemia is a common complication in cardiorenal patients treated with agents interfering with renal potassium (K+) excretion. It frequently leads to discontinuation of potentially life-saving medication, which has increased the importance of K+ monitoring. Non-invasive means to detect hyperkalemia are currently unavailable, but would be of potential use for therapy guidance. The aim of the present study was to assess the analytical performance of genetically encoded potassium-ion indicators (GEPIIs) in measuring salivary [K+] ([K+]Saliva) and to determine whether changes of [K+]Saliva depict those of [K+]Plasma.
METHODS
We conducted this proof-of-concept study: saliva samples from 20 healthy volunteers as well as plasma and saliva from 29 patients on hemodialysis (HD) before and after three consecutive HD treatments were collected. We compared [K+]Saliva as assessed by the gold standard ion-selective electrode (ISE) with GEPII measurements.
RESULTS
The Bland-Altmann analysis showed a strong agreement (bias 0.71; 95% limits of agreement from -2.79 to 4.40) between GEPII and ISE. Before treatment, patients on HD showed significantly higher [K+]Saliva compared with healthy controls [median 37.7 (30.85; 48.46) vs 23.8 (21.63; 25.23) mmol/L; P < .05]. [K+]Plasma in HD patients decreased significantly after dialysis. This was paralleled by a significant decrease in [K+]Saliva, and both parameters increased until the subsequent HD session. Despite similar kinetics, we found weak or no correlation between [K+]Plasma and [K+]Saliva.
CONCLUSION
GEPIIs have shown an excellent performance in determining [K+]Saliva. [K+]Plasma and [K+]Saliva exhibited similar kinetics. To determine whether saliva could be a suitable sample type to monitor [K+]Plasma, further testing in future studies are required.

Identifiants

pubmed: 35700151
pii: 6608365
doi: 10.1093/ndt/gfac195
doi:

Substances chimiques

Potassium RWP5GA015D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

757-763

Subventions

Organisme : Austrian Science Fund FWF
ID : I 3716
Pays : Austria

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.

Auteurs

Andras T Deak (AT)

Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Katarina Belić (K)

Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Anna-Maria Meissl (AM)

Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Katharina Artinger (K)

Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Kathrin Eller (K)

Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Bernd Rechberger (B)

Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Tobias Niedrist (T)

Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.

Wolfgang F Graier (WF)

Gottfried Schatz Research Center (for Cell Signaling, Metabolism and Aging, Division of Molecular Biology and Biochemistry), Medical University of Graz, Graz, Austria.

Roland Malli (R)

Gottfried Schatz Research Center (for Cell Signaling, Metabolism and Aging, Division of Molecular Biology and Biochemistry), Medical University of Graz, Graz, Austria.

Helmut Bischof (H)

Gottfried Schatz Research Center (for Cell Signaling, Metabolism and Aging, Division of Molecular Biology and Biochemistry), Medical University of Graz, Graz, Austria.

Sandra Burgstaller (S)

Gottfried Schatz Research Center (for Cell Signaling, Metabolism and Aging, Division of Molecular Biology and Biochemistry), Medical University of Graz, Graz, Austria.

Sandra Blass (S)

Gottfried Schatz Research Center (for Cell Signaling, Metabolism and Aging, Division of Molecular Biology and Biochemistry), Medical University of Graz, Graz, Austria.

Alexander Avian (A)

Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.

Alexander R Rosenkranz (AR)

Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Alexander H Kirsch (AH)

Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH